Article (http://www.forbes.com/forbeslife/health/feeds/hscout/2006/11/02/hscout535855.html)
As reported in the Nov. 2 New England Journal of Medicine, an analysis of two trials shows that the addition of epirubicin provides a 30 percent reduction in the risk of relapse and death, said lead researcher Dr. Christopher J. Poole, Macmillan Senior Lecturer in Medical Oncology at the University of Birmingham.
The study is expected to have more of an impact in Europe and elsewhere, since epirubicin is more commonly used overseas than in the United States or Canada, said Dr. Mark Levine, a professor of clinical epidemiology and biostatistics and oncology at McMaster University in Hamilton, Ontario.